An outcomes analysis of 2142 breast reduction procedures.
Abstract
[BACKGROUND] Breast reduction alleviates macromastia symptoms and facilitates symmetrical breast reconstruction after cancer treatment. We investigated a large series of consecutive breast reductions to study important factors that impact outcomes.
[METHODS] An institutional review board-approved, retrospective review of all breast reductions from 1999 to 2009 in a single institution was performed using the medical record for demographics, medical history, physical examination, intraoperative data, and postoperative complications. Multivariate statistical analysis was performed using Stata 1.0. P ≤ 0.05 defined significance.
[RESULTS] Seventeen surgeons performed 2152 consecutive breast reductions on 1148 patients using inferior pedicle/Wise pattern (56.4%), medial pedicle/Wise pattern (16.8%), superior pedicle/nipple graft/Wise pattern (15.1%), superior pedicle/vertical pattern (11.6%), and liposuction (0.1%) techniques. Complications included discernible scars (14.5%), nonsurgical wounds (13.5%), fat necrosis (8.2%), infection (7.3%), wounds requiring negative pressure wound therapy or reoperation (1.4%), and seroma (1.2%). Reoperation rates were 6.7% for scars, 1.4% for fat necrosis, and 1% for wounds.Body mass index greater than or equal to 35 kg/m increased risk of infections [odds ratio (OR), 2.3, P = 0.000], seromas (OR, 2.9, P = 0.03), fat necrosis (OR, 2.0, P = 0.002), and minor wounds (OR, 1.7, P = 0.001). Cardiac disease increased reoperation for scar (OR, 3.0, P = 0.04) and fat necrosis (OR, 5.3, P = 0.03). Tobacco use increased infection rate (OR, 2.1, P = 0.008). Secondary surgery increased seromas (OR, 12.0, P = 0.001). Previous hysterectomy/oophorectomy increased risk of wound reoperations (OR, 3.4, P = 0.02), and exogenous hormone supplementation trended toward decreasing infections (OR, 0.5, P = 0.08). χ analysis revealed 7.8% infection risk without exogenous hormone versus 3.8% risk with hormone supplementation (P = 0.02).
[CONCLUSIONS] Morbid obesity, tobacco, cardiac history, and secondary surgery negatively impacted breast reduction outcomes. Hormonal status impacted reoperations and infections.
[METHODS] An institutional review board-approved, retrospective review of all breast reductions from 1999 to 2009 in a single institution was performed using the medical record for demographics, medical history, physical examination, intraoperative data, and postoperative complications. Multivariate statistical analysis was performed using Stata 1.0. P ≤ 0.05 defined significance.
[RESULTS] Seventeen surgeons performed 2152 consecutive breast reductions on 1148 patients using inferior pedicle/Wise pattern (56.4%), medial pedicle/Wise pattern (16.8%), superior pedicle/nipple graft/Wise pattern (15.1%), superior pedicle/vertical pattern (11.6%), and liposuction (0.1%) techniques. Complications included discernible scars (14.5%), nonsurgical wounds (13.5%), fat necrosis (8.2%), infection (7.3%), wounds requiring negative pressure wound therapy or reoperation (1.4%), and seroma (1.2%). Reoperation rates were 6.7% for scars, 1.4% for fat necrosis, and 1% for wounds.Body mass index greater than or equal to 35 kg/m increased risk of infections [odds ratio (OR), 2.3, P = 0.000], seromas (OR, 2.9, P = 0.03), fat necrosis (OR, 2.0, P = 0.002), and minor wounds (OR, 1.7, P = 0.001). Cardiac disease increased reoperation for scar (OR, 3.0, P = 0.04) and fat necrosis (OR, 5.3, P = 0.03). Tobacco use increased infection rate (OR, 2.1, P = 0.008). Secondary surgery increased seromas (OR, 12.0, P = 0.001). Previous hysterectomy/oophorectomy increased risk of wound reoperations (OR, 3.4, P = 0.02), and exogenous hormone supplementation trended toward decreasing infections (OR, 0.5, P = 0.08). χ analysis revealed 7.8% infection risk without exogenous hormone versus 3.8% risk with hormone supplementation (P = 0.02).
[CONCLUSIONS] Morbid obesity, tobacco, cardiac history, and secondary surgery negatively impacted breast reduction outcomes. Hormonal status impacted reoperations and infections.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 해부 | breast
|
유방 | dict | 7 | |
| 합병증 | necrosis
|
괴사 | dict | 4 | |
| 시술 | breast reduction
|
유방성형술 | dict | 3 | |
| 합병증 | infection
|
감염 | dict | 3 | |
| 시술 | liposuction
|
지방흡입 | dict | 1 | |
| 해부 | medial pedicle/Wise
|
scispacy | 1 | ||
| 해부 | fat
|
scispacy | 1 | ||
| 해부 | Cardiac
|
scispacy | 1 | ||
| 합병증 | seroma
|
장액종 | dict | 1 | |
| 합병증 | wounds
|
scispacy | 1 | ||
| 합병증 | wound
|
scispacy | 1 | ||
| 합병증 | seromas
|
scispacy | 1 | ||
| 약물 | [BACKGROUND] Breast
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS]
|
scispacy | 1 | ||
| 질환 | macromastia
|
C0020565
Hypertrophy of Breast
|
scispacy | 1 | |
| 질환 | cancer
|
C0006826
Malignant Neoplasms
|
scispacy | 1 | |
| 질환 | breast reductions
|
C0191922
Reduction mammaplasty
|
scispacy | 1 | |
| 질환 | infections
|
C0851162
Infections of musculoskeletal system
|
scispacy | 1 | |
| 질환 | seromas
|
C0262627
Seroma
|
scispacy | 1 | |
| 질환 | Cardiac disease
|
C0018799
Heart Diseases
|
scispacy | 1 | |
| 질환 | obesity
|
C0028754
Obesity
|
scispacy | 1 | |
| 질환 | scar
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | Tobacco
|
scispacy | 1 |
MeSH Terms
Adolescent; Adult; Aged; Breast; Female; Humans; Hypertrophy; Mammaplasty; Middle Aged; Multivariate Analysis; Odds Ratio; Postoperative Complications; Reoperation; Retrospective Studies; Risk Factors; Treatment Outcome; Young Adult
📑 인용 관계
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- The impact of three-dimensional simulation and virtual reality technologies on surgical decision-making and postoperative satisfaction in aesthetic surgery: a preliminary study.
- Cutaneous fistula of the breast: A complication of cosmetic autologous fat transfer.
- Epidermal inclusion cyst after breast reduction mammoplasty.
- Penetrating globe injury following periocular hyaluronic acid filler injection: A case report.
- Clinical outcomes of synthetic absorbable mesh use in breast surgery: First case series in reconstruction and aesthetic mastopexy.